MAP2K7 and neoplasm: It became evident that although treatment with BRAFi resulted in high objective response rates (ORRs) in the range of 50%–60% with rapid tumor regression, the effect was transient, with a short median progression-free survival (mPFS) of 7 months,13 14 because resistance to BRAFi arises quickly.15 With the addition of a MEK inhibitor, the response rates and overall survival (OS) were further improved, but durable responses are rare and mPFS is only 11 months,16 17 leaving a large space of unmet need.